Position in ATHE
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$201,895
+$132,028 QoQ
Shares Held
37,597
+87.3% QoQ
Ownership
0.207%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#5
of 22 holders
Holding Since
Jun 2021
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ATHE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026CITADEL ADVISORS LLC holds $6,088,670,159 across 436 Biotechnology names. ATHE ranks #319 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ONC |
BeOne Medicines Ltd.
|
1,425,517 | $406,229,578 | |
| 2 | BBIO |
BridgeBio Pharma, Inc.
|
3,760,028 | $280,046,885 | |
| 3 | INSM |
INSMED Inc
|
2,556,973 | $272,624,460 | |
| 4 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
507,233 | $272,358,759 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
510,430 | $253,545,893 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
1,006,676 | $242,578,715 | |
| 7 | MANE |
Veradermics, Inc
|
1,877,775 | $230,853,658 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
5,576,261 | $197,343,876 |
All Filings in ATHE
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $201,895 | 37,597 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $69,867 | 20,077 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $51,777 | 16,811 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $83,261 | 22,144 | Shares | Defined | 2025-11-14 | |
| 2024-09-30 | $15,049 | 11,488 | Shares | Defined | 2024-11-14 | |
| 2024-03-31 | $37,837 | 18,279 | Shares | Defined | 2024-05-15 | |
| 2022-03-31 | $19,568 | 23,576 | Shares | Defined | 2022-05-16 | |
| 2021-09-30 | $14,936 | 11,761 | Shares | Defined | 2021-11-15 | |
| 2021-06-30 | $49,374 | 37,980 | Shares | Defined | 2021-08-16 | |
| No filing history on record for this holder in this stock. | ||||||